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Objective:  
Analgesia and early quality of recovery may be improved by epidural analgesia.  We aimed 
to assess the effect of receiving epidural analgesia on surgical adverse events and quality of 
life after laparotomy for endometrial cancer.  
Methods:  
Patients were enrolled in an international, multicentre, prospective randomised trial of 
outcomes for laparoscopic versus open surgical treatment for the management of apparent 
stage I endometrial cancer (LACE trial). 
The current analysis focussed on patients who received an open abdominal hysterectomy via 
vertical midline incision only (n=257), examining outcomes in patients who did (n=108) and 
did not (n=149) receive epidural analgesia.   
Results:  
Baseline characteristics were comparable between patients with or without epidural 
analgesia.  More patients without epidural (34%) ceased opioid analgesia 3-5 days after 
surgery compared to patients who had an epidural (7%; p<0.01).   Postoperative 
complications (any grade) occurred in 86% of patients with and 66% without an epidural 
(p<0.01) but there was no difference in serious adverse events (p=0.19).  Epidural analgesia 
was associated with increased length of stay (up to 48 days compared to up to 34 days in the 
non-epidural group). There was no difference in postoperative quality of life up to six months 
after surgery. 
Conclusions:  
Epidural analgesia was associated with an increase in any, but not serious, postoperative 
complications and length of stay after abdominal hysterectomy.  Randomised controlled trials 
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are needed to examine the effect of epidural analgesia on surgical adverse events, especially 
as the present data do not support a quality of life benefit with epidural analgesia. 
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Introduction 
Endometrial cancer is the most common gynaecological malignancy in developed countries 
with an estimated 287,000 new cases yearly worldwide[1], and 80% of cases are diagnosed at 
early stages (I or II) [2,3].  Advanced age and an oversupply of endogenous or exogenous 
oestrogen are well established risk factors for endometrial cancer and patients often have 
comorbidities such as obesity, diabetes mellitus and hypertension [4-7]. The primarily 
surgical treatment of endometrial cancer generally yields excellent survival outcomes [8]. 
Traditionally, surgery has been performed through a laparotomy (total abdominal 
hysterectomy; TAH) through a lower transverse or a midline abdominal incision, with or 
without epidural analgesia, and this is still the most common surgical approach in many 
countries worldwide.  Compared to systemic analgesia, epidural analgesia is thought to 
provide better pain relief and reduce the risk of postoperative respiratory failure [9,10].  
Other than reduced risk of respiratory failure, current literature does not suggest a morbidity 
or mortality benefit for epidural analgesia and there is insufficient evidence to determine if 
epidural analgesia improves postoperative quality of life [11-13].  
Previously, we reported results from the Laparoscopic approach to the treatment of 
endometrial cancer (LACE) trial, which enrolled 760 patients with stage I endometrial 
cancer. Patients were randomised to TAH or total laparoscopic hysterectomy (TLH). TLH 
demonstrated reduced surgical adverse events (AEs) and improved quality of life (QOL) up 
to six months after surgery [14-16]. For the aim of this research, we assessed the surgical 
outcomes for women who did or did not have epidural analgesia.  More specifically, we 
examined the impact of epidural analgesia on the outcomes (adverse events (AE), pain, 
quality of life (QOL)) for up to six months after surgery in the subset of 257 patients from the 
LACE trial who had surgery for endometrial cancer through a vertical midline incision.  
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Methods 
Study design 
Between October 2005 and June 2010, 760 women with apparent stage I endometrial cancer 
were enrolled in the LACE trial (ClinicalTrials.gov NCT00096408; Australian New Zealand 
Clinical Trials Registry CTRN12606000261516).  Institutional Review Board approval was 
obtained from all 22 hospitals where patients were recruited and all patients provided written 
informed consent. Study design, early surgical recovery, postoperative QOL, surgical safety 
and costs were reported previously [14,16-18].  Briefly, eligible patients were 18 years or 
older, had histologically confirmed endometrioid endometrial adenocarcinoma, had disease 
apparently confined to the uterus (Stage 1), were medically fit for surgery, and had Eastern 
Cooperative Oncology Group (ECOG) performance status of zero or one.   
 For the aim of the present research question, we restricted analysis to women who had a 
hysterectomy through a vertical midline incision (n=258), excluding patients who had other 
types of incisions or laparoscopic surgery. 
 
Preoperative data collection 
A comprehensive surgical and medical history was taken prior to surgery. Medical 
comorbidities were recorded, classified and scored according to Charlson et al. [19]  Patients 
also completed questionnaires on relevant social and demographic variables.  
Surgical data collection 
Intraoperative details and any complications were documented immediately after surgery 
including length of operating time (skin incision to wound closure).  Length of hospital stay 
was measured from the day of surgery (day 0) to discharge.  Postoperative drop in 
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hemoglobin was measured from baseline to postoperative day one. Transfusions were 
recorded. 
Analgesic data collection 
Analgesics were classified as opioid, non-steroidal anti-inflammatory drugs (NSAIDs) and 
paracetamol from free-text entries of medications given after surgery.  Opioid analgesics 
were further classified by route of administration (epidural, parenteral or oral). 
Opioids included Codeine, Aspirin+Codeine, Paracetamol+Codeine, 
Paracetamol+Codeine+Doxylamine, Paracetamol+Dextropropoxyphene, Tramadol, 
Morphine, Fentanyl,  Oxycodone, Methadone, Pethidine, Hydromorphone, Buprenorphine.  
Combinations of opioids with other drugs were considered as opioids. NSAIDs included 
Aspirin, Ibuprofen, Naproxen, Celecoxib, Indomethacin, Ketorolac, Lumiracoxib, 
Meloxicam, Parecoxib, Piroxicam, Sulindac, and Tiaprofenic acid.   
Duration of epidural analgesia was recorded.  To account for patients whose analgesic 
requirements varied or restarted over time, the percentage of patients using each group of 
analgesia was reported in time periods.  The time periods after surgery were 0-2 days, 3-5 
days, 6-14 days, 15-60 days and 61-150 days.  
Adverse Events (AEs) 
Postoperative AEs were recorded at 1 week, 4 weeks, 3 and 6 months using the National 
Cancer Institute Common Terminology Criteria for Adverse Events (CTC AE) 3.0.[20] This 
system classifies AEs into five grades: (1) mild, (2) moderate, (3) severe, (4) life-threatening 
or disabling AE, and (5) death related to AE.  For the purpose of this analysis, any and all 
AEs in the CTC AE were considered an end-point. 
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A serious AE was defined as any event that resulted in death, was immediately life 
threatening, required inpatient hospitalisation or prolongation of existing hospitalisation, or 
that resulted in persistent or substantial disability or incapacity.  All serious AEs were 
reviewed by an independent safety committee.  Clinicians managed all AEs according to their 
local guidelines and patients were followed-up until satisfactory resolution or until the 
principal investigator or co-investigator deemed the event to be chronic or the patient was 
assessed to be stable. Serious AEs were the second main outcome of interest for the present 
analysis. 
Quality of life 
QOL was assessed by the EQ-5D™ (EuroQol Group, The Netherlands), which is a 
standardised instrument measuring self-reported health status at the time of completion.  The 
EQ-5D was administered at 1 week, 4 weeks, 3 months, and 6 months after surgery.  A global 
Health State assessment (using a visual analogue scale) and global post-surgical pain score 
(using a numerical rating scale) were also assessed at these times.  EQ-5D, and pain score 
questionnaires were used for the present analysis as they were available for all patients. In the 
first 332 of the total of 760 patients, Functional Assessment of Cancer Therapy-General 
(FACT-G, FACIT.org, USA) was also completed (data not used for present analysis).  
Statistical analysis 
All comparisons were two-sided and differences were considered significant if the p-value 
was less than 0.05.  No adjustment was made for multiple comparisons.  No data were 
imputed.  Patients who had completed at least 6 weeks of follow-up after surgery were 
included in this analysis (n=257; one patient withdrew from the trial a week after surgery). 
Baseline demographic and clinical characteristics were compared between patients with open 
abdominal surgery using a vertical midline incision who did or did not receive epidural using 
descriptive statistics, Student’s t-tests and chi-squared tests as appropriate. The proportion of 
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patients with any, or a serious adverse event, and requiring postoperative analgesics within 
each of the follow-up periods was compared using chi-squared tests of heterogeneity. 
Unpaired Student's t-tests were used to compare mean operating time, mean post-operative 
drop in haemoglobin, QOL measured by EQ5D index, and health state visual analogue scale 
scores, between patients with or without epidural. Due to their non-normal distributions, 
Charlson’s comorbidity index, length of hospital stay and pain scores were compared with 
the Wilcoxon rank sum test. Bivariate and multivariate logistic regression was performed to 
assess the effect of preoperative demographic and clinical factors and epidural on the 
occurrence of postoperative complications. In addition, to assess whether length of stay, 
independent of epidural use, was associated with adverse event of any CTC AE category, a 
logistic regression was performed. Due to a skewed distribution, length of stay was log-
transformed prior to logistic modelling and odds ratio findings were back-transformed to 
original unit of length of stay. Statistical analyses were done with SAS software version 9.3 
and STATA 11.  
Results 
 
In total, 258 of 753 LACE trial patients received a vertical midline incision (247 from the 
TAH arm and 11 conversions from the TLH arm) and 257 completed at least 6 weeks of 
follow-up after surgery and were eligible for this analysis.  Epidural analgesia was provided 
for 108 patients and 149 did not receive epidural analgesia (Figure 1). 
Patients who received or did not receive an epidural analgesia did not differ in their baseline 
characteristics including age, BMI, socioeconomic indicators, ECOG performance status, 
comorbidity index, or cancer stage (Table 1). 
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For the 108 patients who received an epidural, mean duration of epidural analgesia was 1.66 
days (SD 0.88, range 1-4 days). Table 2 reports the route of administration of post-operative 
analgesia during the first two days after surgery, the type of medication used at anytime 
during recovery and the type of medication during post-operative recovery periods.  
Compared to patients with an epidural (66%), patients who did not have an epidural were 
more likely to receive parenteral opioid analgesia during the first two days post-surgery 
(97%; p<0.01).  However, two-thirds of patients in the epidural group also required 
parenteral opioids. At any time during recovery, patients with an epidural (59%) were less 
likely to also receive NSAIDs compared to patients without an epidural (73%; p=0.02). 
NSAIDs were more frequently used by patients without epidural analgesia during the first 
two days after surgery (p<0.01).  A greater proportion of patients without epidural (34%) 
ceased opioid analgesia 3-5 days after surgery compared to patients who had an epidural 
(7%; p<0.01).  This effect continued for the 6-14 day period after surgery (p<0.05).  There 
were no  significant differences in analgesia use between the groups during the time periods 
15-60 days or 61-150 days after surgery (Table 2).  
The incidence of any intraoperative surgical AEs (p=0.21) or serious postoperative AEs 
(p=0.19) was comparable between the two groups (Table 3). By contrast, the incidence of 
postoperative surgical AEs (any grade) was higher in the epidural than in the non-epidural 
group (p<0.01) (Table 3). Bivariate logistic regression found epidural use to be significantly 
associated with occurrence of postoperative adverse events of any CTC AE grade (Odds ratio 
3.23; 95% Confidence Interval (CI) 1.67-6.13, p<0.001). Patients with a higher Charlson 
Index score were also somewhat more likely to have AEs although this did not reach 
statistical significance (Odds ratio 1.13; 95% CI 0.95-1.35, p<0.17). No other preoperative 
clinical or demographic factors described in Table 1 were  significantly associated with AEs 
(data not shown). Multivariate logistic regression also did not find any preoperative factors to 
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be associated with occurrence of postoperative adverse events in addition to epidural use 
(data not shown). 
 
The hospital length of stay (LOS) was longer in the epidural group (p=0.02).  The median 
LOS was 5 days in both groups but the distribution of LOS was skewed and more patients 
with an epidural experienced a prolonged length of stay (Table 4).  From logistic regression, 
we estimate that every additional day of hospital stay is associated with increased odds of an 
AE occurring of 3.41 (95% CI 1.69-6.86, p<0.001). However, when epidural use was added 
to this regression analysis, the strength of the association was reduced somewhat  (Odds ratio 
1.76 per additional day, 95% CI 0.99-3.15, p 0.06). There were no in-hospital deaths, or 
deaths during the six month period after surgery in either group.    
 
The mean drop of haemoglobin from baseline to postoperative day 1 was 18 g/L and 23 g/L 
in the no-epidural and epidural groups, respectively (p<0.01). QOL measures (EQ5-D, health 
state) and pain scores did not differ significantly between the groups in the follow up period. 
According to the Health Services Use questionnaire, patients who had an epidural reported 
more physician visits other than their gynaecologic oncologists at the 4 week, 3 months and 6 
months follow-up visits to the clinic  (Table 4). 
Discussion 
The LACE study examined outcomes for women with apparent stage 1 endometrial cancer 
with good functional capacity (ECOG 0 and 1).  While the two groups of patients (vertical 
midline incision with or without epidural analgesia) studied in this subgroup analysis were 
not randomised, they were well matched for baseline demographics, socioeconomic 
measures, functional status, medical comorbidities, pathological grade and stage, and surgical 
procedure.  The use of epidurals in this study was associated with more postsurgical AEs 
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overall, an increased duration of hospital stay, a greater fall in postoperative haemoglobin, 
and more frequent physician visits from 4 weeks to 6 months after surgery. However there 
was no significant difference between the two groups in serious adverse events. 
The pattern of analgesic use was different between the groups in the first two weeks after 
surgery.  During the first two days after surgery, patients without an epidural were more 
likely to receive NSAIDs but after this time, NSAID use was similar. The proportion of 
patients requiring opioids was higher between 3 and 14 days in patients who were given an 
epidural. In the absence of any evidence from the literature, we can only speculate that 
NSAID use in the first 48 hours facilitates earlier transition to non-opioid analgesia through 
their anti-inflammatory and analgesic effect, via prostaglandin biosynthesis inhibition [21]. 
Alternatively, epidurals may delay the transition to non-opioid analgesia. 
Our study demonstrated no significant difference in QOL outcomes or pain scores from one 
week to six months after surgery.  Epidural analgesia typically demonstrates a modest benefit 
in pain scores for 48 to 72 hours after surgery [10,22,23].  A difference would not be 
expected in our study because the pain score was first assessed at one week. Quality of 
recovery has been found to be better 24 hours after hysterectomy with epidural analgesia 
[24]. Two studies in thoracic and abdominal surgery found epidural analgesia improved 
postoperative QOL [25,26], but other studies were negative [26-28]. A systematic review 
concluded that there was insufficient evidence to determine if epidural analgesia has an effect 
on QOL [29].  It is likely that any benefit in pain scores or QOL with epidural analgesia 
would be restricted to the very early postoperative period. Our data does not support an effect 
between 1 week and 6 months after surgery. 
In our study, AEs were recorded when patients had at least one CTC AE after surgery.  The 
AE rate (counting all minor to major events) was 86% and 66% with and without an epidural, 
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respectively.  Gastrointestinal, constitutional and infectious complications were the most 
common AEs contributing to the difference between groups (Table 3). No other pre-operative 
difference was found between the groups that could explain the difference in AEs.  Epidural 
analgesia does not improve survival but has been proposed as beneficial in abdominal surgery 
because of improved analgesia, reduced respiratory complications and earlier return of bowel 
function [10,12,30,31].  The benefits in bowel or respiratory AEs were not demonstrated in 
our study.  However, larger numbers of patients would be required in each group to assess 
which of the individual AEs are more likely with an epidural.  An increased length of stay 
was observed in the epidural group.  In keeping with the literature, AEs were associated with 
increased duration of admission [32]. There was no statistically significant difference for 
serious AEs between the groups, potentially due to insufficient sample size given the very 
small number of such events.  
The fall in haemoglobin was 5g/l larger on the day after surgery in patients with an epidural.  
Typically, neuraxial anaesthesia is associated with reduced intraoperative blood loss [33]. In 
our case, epidural analgesia probably required additional fluid therapy and hemodilution is 
the most likely explanation for the larger fall in hemoglobin.  To assess whether differences 
in fluid therapy could explain the difference in hemoglobin, weights recorded before surgery 
and one week after surgery were compared.  Data was not available for all patients and the 
result was not statistically significant.  Patients with an epidural gained an average of 0.29kg 
(n=35) and without an epidural lost 0.39kg (n=57, p=0.54).  Further investigation is required 
to determine if i.v. fluid therapy required with epidural analgesia causes the fall in 
hemoglobin. 
Finally, patients in the epidural group also had more frequent visits to medical practitioners 
other than their surgeons after surgery.  Whether this is due to analgesia, the increased 
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incidence of AEs, or other factors cannot be determined from the data, but should be 
investigated in future studies. 
All patients survived the 6-month follow-up period.  Meta-analysis of older studies showed 
reduced postoperative mortality with spinal and epidural analgesia but randomised studies 
have not demonstrated a benefit [10,23,34].  Large population based studies demonstrate a 
small decrease in mortality associated with epidural analgesia [35,36]. The patients in our 
study had good functional status, early stage cancer and presented for elective surgery and 
can expect low perioperative mortality.  It would require a very large sample to assess any 
effect of epidural analgesia on mortality in this population. 
This is a subgroup analysis of a randomised trial comparing TAH with TLH, patients were 
not randomised to the epidural or non-epidural groups, and bias cannot be excluded in this 
study.  Selection bias is possible if anaesthetists recommended epidural analgesia to patients 
with increased comorbidity and risk, however this appears unlikely as both groups had 
similar Charlson comorbidity index (Table 1).   
This study recruited participants between 2005 and 2010.  During that time, there was an 
increase in literature and popularity of transversus abdominis plane (TAP) blocks and other 
regional anaesthetics for abdominal surgery[37].  We did not evaluate the use or effects of 
these techniques during the study period.  We also did not estimate or measure the costs of 
epidural analgesia in our study.  Others studies have shown that epidural analgesia is 
associated with increased cost compared to intravenous analgesia in abdominal surgery[38]. 
An evaluation of epidural, intravenous and continuous wound infiltration analgesic 
techniques suggested that continuous wound infiltration is the most cost effective analgesic 
technique in open abdominal surgery[39]. 
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The use of epidural analgesia is often institution dependent and the difference found in this 
secondary data analysis may reflect differences in outcomes between institutions rather than 
techniques.  As this data comes from cases performed in 22 hospitals, the number of cases at 
each hospital was too small to independently assess the effect of institution on outcome.   For 
the same reason, the influence of institution specific “enhanced recovery programs” (ERPs) 
or “fast track surgery” cannot be assessed.  Thoracic epidural analgesia has been promoted as 
a component of ERPs for abdominal surgery[40]. However, as we have not found a benefit 
associated with epidural analgesia, it seems reasonable to question their role in ERPs after 
hysterectomy for endometrial cancer.  
 
The strengths of the analysis include the very similar baseline characteristics of the two 
groups, and the prospective, detailed recording of AEs by independent observers. 
 
Our data demonstrate no benefit with epidural analgesia in a population of women with early 
stage endometrial cancer and good functional capacity who could expect a good recovery and 
prognosis after surgery.  Epidural analgesia in this population may be associated with a wide 
variety of postoperative complications but our findings should be interpreted cautiously 
because of the non-randomised assignment of patients to receive or not receive epidural 
analgesia, and the potential for residual confounding.  Similarly, we should not extend the 
conclusions to patients with significantly impaired functional status, more advanced cancers 
or ovarian cancer where morbidity and mortality will be higher.  Further assessments of 
surgical AEs with epidural analgesia in a randomised controlled trial involving surgical 
primary study endpoints rather than anaesthetic endpoints are required.  
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Table	1:	Baseline	characteristics	
      Epidural       
     
No 
(N=149)* 
Yes 
(N=108)*  P‐value    
   Age in years, mean(SD)  63 (10)  63 (10)  0.999    
   BMI mean(SD)  34 (8)  33 (7)  0.47    
     Category†  0.96    
     Normal (18.50‐24.99)  19 (13)  13 (13)    
     Overweight (25.00‐29.99)  31 (22)  24 (23)    
     Obesity class I (30.00‐34.99)  37 (26)  30 (29)    
     Obesity class II (35.00‐39.99)  29 (20)  20 (19)    
     Obesity class III (≥40)  28 (19)  17 (16)    
   Education        0.87    
     Completed ≤12 years of school  101 (73)  76 (72)       
     Completed >12 years of school  38 (27)  30 (28)       
   Employment  0.47    
     Retired  56 (40)  52 (49)    
     Employed full‐time  18 (13)  9 (8)    
     Employed part‐time or casual  21 (15)  16 (15)    
     Other  44 (32)  29 (27)    
   Marital status        0.89    
     Married or living together  88 (63)  68 (64)       
     Other  51 (37)  38 (36)       
   Private health insurance  0.71    
     Yes  30 (22)  25 (24)    
     No  109 (78)  81 (76)    
   Income        0.24    
     Less than AUS$40,000  86 (62)  75 (71)       
     AUS$40,000+  29 (21)  20 (19)       
     Not answered  24 (17)  11 (10)       
   Birth country  0.89    
     Australia  88 (63)  68 (64)    
     Other  51 (37)  38 (36)    
   ECOG performance status        0.58    
   0  126 (85)  94 (87)       
   1  23 (15)  14 (13)       
  
Baseline analgesic use  (patients counted more than once if taking more 
than one analgesic)    
   Opioid  7 (5)  1 (0.9) 
0.08 
(Fisher)    
   NSAID  31 (21)  31 (29)  0.14    
   Paracetamol  21 (14)  14 (13)  0.79    
   No analgesia  90 (60)  62 (57)  0.63    
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Table	1:	Baseline	characteristics	(continued)	
      Epidural       
     
No 
(N=149)* 
Yes 
(N=108)*  P‐value    
   Charlson comorbidity index#             
   mean(SD)  2.9 (1.7)  3.1 (1.6)  0.49    
   median (range)  3 (0‐8)  3 (0‐8)  0.82    
   0  5 (3)  1 (1)  0.76    
   1  25 (17)  18 (17)       
   2  37 (25)  25 (23)       
   3  39 (26)  28 (26)       
   4  17 (11)  13 (12)       
   5  13 (9)  14 (13)       
   6  5 (3)  6 (6)       
   7  7 (5)  2 (2)       
   8  1 (0.7)  1 (0.9)       
   9  ‐  ‐       
   10  ‐  ‐       
   Baseline haemoglobin: mean(SD)  134 (13)  135 (13)  0.32    
   Grade on D&C        0.13    
   1  85 (57)  61 (56)       
   2  55 (37)  33 (31)       
   3  9 (6)  14 (13)       
   Histological grade  0.33    
   1  78 (52)  47 (44)    
   2  53 (36)  41 (38)    
   3  18 (12)  18 (17)    
   Nodal dissection performed  97 (65)  72 (67)  0.79    
   FIGO stage  0.33    
   I  112 (75)  86 (80)    
   II  27 (18)  12 (11)    
   III  7 (5)  8 (7)    
   IV  3 (2)  1 (1)    
                 
Numbers do not always add to total number in group due to misisng data 
* Expressed as n(%) unless stated otherwise 
#: The first p‐value is from a T‐test on the Charlson score as a continuous variable. The second p‐value is from 
a Wilcoxon rank‐sum test on the Charlson score to account for skewness. The third p‐value is from a Chi‐
squared test of heterogeneity on the individual scores. 
BMI: body mass index      
ECOG: Eastern Cooperative Oncology Group             
D&C: Dilatation and curettage     
		FIGO:	International	Federation	of	Gynecology	and	Obstetrics	
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Table	2:	Post‐operative	analgesic	use	
	
        Epidural     
      No (N=149) 
Yes 
(N=108)  P‐value*    
      n(%)  n(%)       
   Route of post‐op opioid use (≤2 day post‐op)        
   Epidural  0  103 (95)  ‐    
   Parenteral  145 (97)  71 (66)  <0.01    
   Oral  97 (65)  65 (60)  0.42    
   Nil  3 (2)  1 (1)  0.49    
                 
   Analgesic classes at anytime             
   Opioid  147 (99)  108 (100)  0.23    
   NSAID  109 (73)  64 (59)  0.02    
   Paracetamol  147 (99)  107 (99)  0.76    
   No analgesia  0 (0)  0 (0)  ‐    
                 
   Analgesic classes 0‐2 days post‐op          
   Opioid  147 (99)  108 (100)  0.23    
   NSAID  101 (68)  49 (45)  <0.01    
   Paracetamol  146 (98)  107 (99)  0.49    
   No analgesia  ‐  ‐  ‐    
   Analgesic classes 3‐5 days post‐op          
   Opioid  98 (66)  100 (93)  <0.01    
   NSAID  56 (38)  38 (35)  0.69    
   Paracetamol  136 (91)  97 (90)  0.69    
   No analgesia  8 (5)  2 (2)  0.15    
   Analgesic classes 6‐14 days post‐op        
   Opioid  47 (32)  47 (44)  0.05    
   NSAID  30 (20)  25 (23)  0.56    
   Paracetamol  91 (61)  73 (68)  0.28    
   No analgesia  44 (30)  21 (19)  0.07    
   Analgesic classes 15‐60 days post‐op          
   Opioid  22 (15)  16 (15)  0.99    
   NSAID  15 (10)  12 (11)  0.79    
   Paracetamol  55 (37)  42 (39)  0.75    
   No analgesia  81 (54)  57 (53)  0.80    
   Analgesic classes 61‐150 days post‐op          
   Opioid  6 (4)  5 (5)  0.81    
   NSAID  6 (4)  5 (5)  0.81    
   Paracetamol  19 (13)  14 (13)  0.96    
   No analgesia  123 (83)  89 (82)  0.98    
              
  NSAID: Non‐steroidal anti‐inflammatory drugs  
*	P	values	reported	using	a	χ2	comparison	between	groups	
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Table	3:	Intraoperative	and	postoperative	complications	
	
      Epidural       
     
No       
(N=149) 
n(%) 
Yes       
(N=108)     
n(%)  p value    
   Intraoperative complications             
   Any  13 (9)  5 (5)  0.21    
   Bowel injury  6 (4)  2 (2)    
   Vaginal injury  ‐  ‐    
   Vascular injury  3 (2)  1 (1)    
   Bladder injury  3 (2)  ‐    
   Blood transfusion  1 (0.7)  2 (2)    
   Ureter injury  2 (1)  ‐    
   Nerve injury  ‐  ‐    
  
Postoperative complications, all CTC AE 
grades          
   Any  99 (66)  93 (86)  <0.01    
   Wound infection/dehiscence  69 (46)  52 (48)    
   Infection  27 (18)  33 (31)    
   Gastrointestinal/hepatobiliary  46 (31)  49 (45)    
   Pulmonary/upper respiratory  33 (22)  31 (29)    
   Constitutional symptoms  39 (26)  38 (35)    
   Renal/genitourinary  10 (7)  17 (16)    
   Cardiac general  16 (11)  18 (17)    
   Neurology  20 (13)  14 (13)    
   Musculoskeletal/soft tissue  15 (10)  15 (14)    
   Blood/bone marrow  9 (6)  12 (11)    
   Metabolic/laboratory 10 (7)  21 (19)    
   Haemorrhage/bleeding  15 (10)  6 (6)    
   Lymphatics  9 (6)  7 (6)    
   Dermatology/Skin  4 (3)  12 (11)    
   Vascular  4 (3)  1 (1)    
   Others  7 (5)  7 (6)    
   Endocrine  ‐  2 (2)    
   Cardiac arrhythmia  4 (3)  3 (3)    
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Table	3:	Intraoperative	and	postoperative	complications	(continued)	
	
      Epidural       
     
No       
(N=149) 
n(%) 
Yes       
(N=108)     
n(%)  p value    
   Serious adverse events             
   Any  27 (18)  13 (12)  0.19    
   Wound infection/dehiscence  15 (10)  6 (6)    
   Haemorrhage/bleeding  7 (5)  ‐    
   Cardiac general  2 (1)  2 (2)    
   Pulmonary/upper respiratory  5 (3)  5 (5)    
   Infection  3 (2)  ‐    
   Neurology  2 (1)  ‐    
   Gastrointestinal/hepatobiliary  ‐  3 (3)    
   Renal/genitourinary  1 (0.7)  ‐    
   Surgery/Intra‐operative injury  1 (0.7)  ‐    
   Vascular  1 (0.7)  ‐    
   Blood/bone marrow  ‐  2 (2)    
   Constitutional symptoms  1 (0.7)  2 (2)    
   Cardiac arrhythmia  3 (2)  2 (2)    
   Endocrine  ‐  ‐    
   Metabolic/laboratory ‐  1 (1)    
   Others  1 (0.7)  ‐    
	
 
CTC AE: National Cancer Institute Common Terminology Criteria for Adverse Events 
grade 
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Table 4: Postoperative outcomes 
 
      Epidural       
   Clinical outcomes 
No              
(N=149) 
Yes        
(N=108)  P‐value*    
   Operating time (mins): mean (SD)  109 (38)  113 (30)  0.37    
   Length of stay: median (range)  5 (3‐34)  5 (3‐48)  0.02    
             
   Post‐op drop in haemoglobin (g/L): mean (SD)  18 (12)  23 (10)  <0.01    
   Transfused n(%)  1 (0.7)  2 (1.9)  0.38    
   Postoperative outcomes             
   Baseline†          
   EQ5D Index: mean(SD)  0.85 (0.11)  0.86 (0.14)  0.63    
   Health state: mean(SD)  75 (20)  76 (17)  0.74    
   Week 1 follow‐up†             
   EQ5D Index: mean(SD)  0.68 (0.18)  0.64 (0.18)  0.10    
   Health state: mean(SD)  64 (23)  61 (21)  0.38    
   Pain score: median (range)  2 (0‐10)  2 (0‐8)  0.28    
  
≥1 visits to doctor other than usual Gyn Onc** 
doctor: n(%)  31 (21)  29 (27)  0.25    
   Week 4 follow‐up†          
   EQ5D Index: mean(SD)  0.84 (0.12)  0.81 (0.15)  0.13    
   Health state: mean(SD)  78 (18)  74 (18)  0.08    
   Pain score: median (range)  0 (0‐7)  0 (0‐8)  0.34    
  
≥1 visits to doctor other than usual Gyn Onc 
doctor: n(%)  68 (45)  66 (61)  0.01    
   Month 3 follow‐up†             
   EQ5D Index: mean(SD)  0.89 (0.13)  0.88 (0.14)  0.43    
   Health state: mean(SD)  82 (18)  80 (18)  0.44    
   Pain score: median (range)  0 (0‐9)  0 (0‐5)  0.29    
  
≥1 visits to doctor other than usual Gyn Onc 
doctor: n(%)  49 (33)  52 (48)  0.01    
   Month 6 follow‐up†          
   EQ5D Index: mean(SD)  0.89 (0.11)  0.90 (0.13)  0.86    
   Health state: mean(SD)  83 (18)  82 (17)  0.68    
   Pain score: median (range)  0 (0‐10)  0 (0‐5)  0.46    
  
≥1 visits to doctor other than usual Gyn Onc 
doctor: n(%)  53 (35)  52 (48)  0.04    
  *P‐value from Wilcoxon test for pain score, χ2 test for doctor visits and T‐test for other outcomes 
  †Numbers differ slightly between rows due to missing values                                                           
 
* Expressed as n(%) unless noted otherwise
**Gynaecological Oncologist         
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Figure 1.  Patient selection for analysis 
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